FI107231B - Förfarande för framställning av tablett för kontrollerade frigöring av verapamil - Google Patents

Förfarande för framställning av tablett för kontrollerade frigöring av verapamil Download PDF

Info

Publication number
FI107231B
FI107231B FI931342A FI931342A FI107231B FI 107231 B FI107231 B FI 107231B FI 931342 A FI931342 A FI 931342A FI 931342 A FI931342 A FI 931342A FI 107231 B FI107231 B FI 107231B
Authority
FI
Finland
Prior art keywords
verapamil
controlled release
ratio
filler
hydrophilic
Prior art date
Application number
FI931342A
Other languages
English (en)
Finnish (fi)
Other versions
FI931342A (fi
FI931342A0 (fi
Inventor
Anand R Baichwal
John N Staniforth
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of FI931342A publication Critical patent/FI931342A/fi
Publication of FI931342A0 publication Critical patent/FI931342A0/fi
Application granted granted Critical
Publication of FI107231B publication Critical patent/FI107231B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • External Artificial Organs (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cephalosporin Compounds (AREA)

Claims (9)

1. Förfarande för framställning av en tablett för kontrollerad frigöring av i verapamil inom mag-tarmomrädet, kännetecknat därav att ett fyllmedel, som frigör 5 kontrollerat och innefattar en hydrofil gummimatris, som bestär av xantangum-mi och karabengummi i förhallanden 3:1 -1:3; och ett inert utspädningsmedel, som valts ur gruppen bestäende av en monosackarid, en disackarid, en poly-hydrisk alkohol och deras blandningar, varvid förhällandet mellan det inerta lösningsmedlet och nämnda hydrofila gummimatris är4:1 - 0,67:1, och en 10 effektiv mängd av verapamil förenas, varvid förhällandet mellan verapamil och nämnda hydrofila gummimatris är 3:1 - 1:3,.
2. Förfarande enligt patentkravet 1, kännetecknat därav att verapamil torrgra-nuleras med nämnda kontrollerad frigöring besittande fyllmedel före tablette- 15 ring.
3. Förfarande enligt patentkravet 1, kännetecknat därav att verapamil vätgra-nuleras med nämnda kontrollerad frigöring besittande fyllmedel före tablettering. 20
4. Förfarande enligt patentkravet 1, kännetecknat därav att en första del av ·.*· · verapamil torrgranuleras med en första del av nämnda kontrollerad frigöring besittande fyllmedel, och en andra del av verapamil vätgranuleras med en an- «· · • V dra del av nämnda kontrollerad frigöring besittande fyllmedel, varvid nämnda *"*·* 25 torrgranulerade del och nämnda vätgranulerade del förenas före tablettering. Il · I
« · « · • · • · · : 5. Förfarande enligt patentkravet 1, kännetecknat därav att förhällandet mel lan xantangummi och karabengummi är 1:1. (MM • · * « · '.... <r 30
6. Förfarande för framställning av en tablett för kontrollerad frigöring av verapa- c mil i mag-tarmomrädet, kännetecknat därav att 45 - 70 % kontollerat frigöran- ((< {' “; de fyllmedel, som bestär av 25 - 55 % hydrofilt ämne, som bestär av xantan- c < v ; <; gummi och karabengummi i förhällandet 1:1, och ett inert utspädningsmedel, « «4 som valts ur gruppen bestäende av en monosackarid, en disackarid, en poly- • · 107231 hydrisk alkohol och deras blandningar och en effektiv mängd av verapamil, for-enas. .
7. Förfarande enligt patentkravet 6, kännetecknat därav, att förhälandet mel-5 Ian verapamil och nämnda hydrofila ämne är 1,0:0,4 -1,0:0,7.
8. Förfarande för framställning av en verapamiltablett, som frigör kontrollerat, kännetecknat därav, att en hydrofil gummimatris, som omfattar xantangumm och karabengummi i förhällanden 1:1, framställs; 10 nämnda hydrofila gummimatris blandas med ett inert utspädningsmedel, som valts ur gruppen bestäende av en monosackarid, en disackarid, en polyhydris* alkohol och deras blandningar sa, att förhällandet mellan nämnda inerta utspädningsmedel och nämnda hydrofila gummimatris är 4:1 - 0, 67:1; 15 blandningen av hydrofil gummimatris/inert utspädningsmedel förenas med verapamil sä, att förhällandet mellan verapamil och blandningen av nämnda hydrofila gummimatris/inert utspädningsmedel är 1,0:0,4 -1,0:0,7; och 20 den erhällna blandningen pressas för att erhälla fasta tabletter med önskad verapamildos, varvid verapamil frigörs enligt en önskad lösningsprofil dä den , * >, j kommer i kontakt med magsaft. • < I I ( «It4
*’·*: 9. Förfarande enligt patentkravet 8, kännetecknat därav att verapamil förenas • · ·:··: 25 med blandningen mellan den hydrofila gummimatrisen/det inerta utspädnings- medlet genom vatgranulering. • « • ·« I « « • · · • « M» t < l f '.1C'· f < t t c 1 1 ( I r I « 4 • « « «I « • ·
FI931342A 1991-07-25 1993-03-25 Förfarande för framställning av tablett för kontrollerade frigöring av verapamil FI107231B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/736,031 US5169639A (en) 1988-09-19 1991-07-25 Controlled release verapamil tablets
US73603191 1991-07-25
PCT/US1992/005712 WO1993001803A1 (en) 1991-07-25 1992-07-02 Controlled release verapamil tablet
US9205712 1992-07-02

Publications (3)

Publication Number Publication Date
FI931342A FI931342A (fi) 1993-03-25
FI931342A0 FI931342A0 (fi) 1993-03-25
FI107231B true FI107231B (sv) 2001-06-29

Family

ID=24958214

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931342A FI107231B (sv) 1991-07-25 1993-03-25 Förfarande för framställning av tablett för kontrollerade frigöring av verapamil

Country Status (17)

Country Link
US (1) US5169639A (sv)
EP (1) EP0550737B1 (sv)
JP (1) JPH0733339B2 (sv)
KR (1) KR0184308B1 (sv)
AT (1) ATE147974T1 (sv)
AU (1) AU649163B2 (sv)
CA (1) CA2092287C (sv)
DE (1) DE69217031T2 (sv)
DK (1) DK0550737T3 (sv)
ES (1) ES2099273T3 (sv)
FI (1) FI107231B (sv)
GR (1) GR3023086T3 (sv)
HU (1) HU218658B (sv)
IE (1) IE922411A1 (sv)
IL (1) IL102614A (sv)
MX (1) MX9204352A (sv)
WO (1) WO1993001803A1 (sv)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
JP2527132B2 (ja) * 1993-08-25 1996-08-21 清水化学株式会社 親水性多糖類よりなる外用薬組成物
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
HU219818B (hu) * 1994-04-25 2001-08-28 Edward Mendell Co. Inc. Elnyújtott hatóanyag-leadású hordozóanyag
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
CA2205351A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
WO1997044025A1 (en) * 1996-05-23 1997-11-27 G.D. Searle & Co. Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil
ES2322405T3 (es) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
IN186245B (sv) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
JP2002531491A (ja) * 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
GB9910212D0 (en) * 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
MXPA03008292A (es) 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosificacion cronoterapeuticas que contienen glucocorticosteroides.
EP1245227A1 (en) * 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
JP2007505921A (ja) 2003-09-19 2007-03-15 ペンウェスト ファーマシューティカルズ カンパニー 遅延放出剤形
CA2652981C (en) * 2006-10-10 2012-05-01 Penwest Pharmaceuticals Co. Robust sustained release formulations
JP5463537B2 (ja) * 2008-02-22 2014-04-09 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 分離方法
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993836A (en) * 1958-02-20 1961-07-25 Dow Chemical Co Sustained release tablets
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
NL265428A (sv) * 1960-06-06
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
GB1097207A (en) * 1964-08-24 1967-12-29 Collett & Co As Process for the preparation of sustained action tablets
US3456049A (en) * 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US3726690A (en) * 1965-10-22 1973-04-10 Kelco Co Acidified food products containing xanthomonas colloid
US3864469A (en) * 1967-12-16 1975-02-04 Hoechst Ag Xanthines in pharmaceutical preparations and for stabilization of vitamins
US3639169A (en) * 1969-04-29 1972-02-01 Sucrest Corp Direct compression vehicles and method therefor
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
FR2183546B1 (sv) * 1972-05-10 1975-06-20 Servier Lab
US3963832A (en) * 1973-01-24 1976-06-15 Teijin Limited Liquid or pasty dentifrice and process for its preparation
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US4013820A (en) * 1974-11-07 1977-03-22 Abbott Laboratories Universally useable tableting ingredients
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
DE2732201C2 (de) * 1977-07-16 1983-01-13 Messerschmitt-Bölkow-Blohm GmbH, 8000 München Regler für die Lagestabilisierung eines Satelliten
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4698101A (en) * 1982-08-30 1987-10-06 Suomen Sokeri Oy (Finnish Sugar Company Ltd.) Binder-diluent composition and method
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPS60219238A (ja) * 1984-04-14 1985-11-01 Hayashibara Biochem Lab Inc 徐崩性プルラン含有成形物とその製法
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4695463A (en) * 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
WO1987000044A1 (en) * 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
GB8608818D0 (en) * 1986-04-11 1986-05-14 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0826346B2 (ja) * 1986-07-10 1996-03-13 株式会社林原生物化学研究所 固状油溶性物質の製法
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
ES2045281T3 (es) * 1988-07-13 1994-01-16 Knoll Ag Forma de medicamento de accion retardada sobre la base de alginatos.
GB8908647D0 (en) * 1989-04-17 1989-06-01 Glaxo Group Ltd Device

Also Published As

Publication number Publication date
IL102614A0 (en) 1993-01-14
FI931342A (fi) 1993-03-25
EP0550737A4 (en) 1993-12-15
MX9204352A (es) 1993-04-01
EP0550737A1 (en) 1993-07-14
HU218658B (hu) 2000-10-28
AU649163B2 (en) 1994-05-12
DE69217031T2 (de) 1997-05-07
JPH06500576A (ja) 1994-01-20
FI931342A0 (fi) 1993-03-25
CA2092287C (en) 1997-03-25
US5169639A (en) 1992-12-08
DE69217031D1 (de) 1997-03-06
HUT64221A (en) 1993-12-28
CA2092287A1 (en) 1993-01-26
AU2403392A (en) 1993-02-23
KR0184308B1 (ko) 1999-05-01
KR930701983A (ko) 1993-09-08
IE922411A1 (en) 1993-01-27
ES2099273T3 (es) 1997-05-16
DK0550737T3 (sv) 1997-02-17
HU9300768D0 (en) 1993-06-28
GR3023086T3 (en) 1997-07-30
IL102614A (en) 1997-02-18
WO1993001803A1 (en) 1993-02-04
EP0550737B1 (en) 1997-01-22
JPH0733339B2 (ja) 1995-04-12
ATE147974T1 (de) 1997-02-15

Similar Documents

Publication Publication Date Title
FI107231B (sv) Förfarande för framställning av tablett för kontrollerade frigöring av verapamil
US5128143A (en) Sustained release excipient and tablet formulation
EP0360562B1 (en) Directly compressible sustained release excipient
US5135757A (en) Compressible sustained release solid dosage forms
FI116450B (sv) Förfarande för framställning av metoprolols 24-timmars formulering
FI118001B (sv) Metoprololdosform som skall intas en gång om dagen genom munnen
US4671823A (en) Sucrose encrusted methyl cellulose particles for use in bulk laxative compositions
JPH01250314A (ja) 徐放性製剤
JPS62181227A (ja) 固体持続放出医薬製剤
JPS63290822A (ja) コレスティラミン組成物およびその製法
JP2002531491A (ja) ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
JP3319625B2 (ja) 速崩壊性生薬製剤
EP1721620A1 (en) Directly-compressible xylitol powder
FI119353B (sv) Fyllnadsmedel som ger fördröjd frigörning
EP2429501B1 (en) Burst drug release compositions
CN113876961B (zh) 一种共处理辅料及其制备方法和用途
CN117398397B (zh) 一种含有帕立骨化醇的组合物及其制备方法
JPH05221853A (ja) 崩壊性良好な生薬類含有造粒物
MXPA94008792A (en) Sustained release formulations for 24 hours of metopro release